Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Kornélia Polyák, Charles Y. Lin et al.|Nature|2016Cited by 629
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancerDaniel G. Stover, Nancy U. Lin, Carlos R. Gil Del Alcazar et al.|npj Breast Cancer|2018Cited by 150
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessOtto Metzger, Daniel G. Stover, W. Fraser Symmans et al.|npj Breast Cancer|2021Cited by 37
The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19Ang Li, Rachel Rosovsky, Nicole M. Kuderer et al.|Journal of Thrombosis and Haemostasis|2021Cited by 30
Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) RegistryAng Li, Rachel Rosovsky, Nicole M. Kuderer et al.|Blood|2020Cited by 8